Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABOS
stocks logo

ABOS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.360
-41.94%
--
--
-0.340
-29.17%
--
--
-0.315
-53.68%
Estimates Revision
Stock Price
Go Up
up Image
+37.50%
In Past 3 Month
Wall Street analysts forecast ABOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABOS is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ABOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABOS is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.980
sliders
Low
4.00
Averages
6.50
High
10.00
Current: 1.980
sliders
Low
4.00
Averages
6.50
High
10.00
BofA
Buy
downgrade
$9 -> $8
2025-11-18
Reason
BofA
Price Target
$9 -> $8
2025-11-18
downgrade
Buy
Reason
BofA lowered the firm's price target on Acumen to $8 from $9 and keeps a Buy rating on the shares, citing an updated cash position following the company's Q3 update.
BTIG
Thomas Shrader
Buy
downgrade
$11 -> $4
2025-10-16
Reason
BTIG
Thomas Shrader
Price Target
$11 -> $4
2025-10-16
downgrade
Buy
Reason
BTIG analyst Thomas Shrader lowered the firm's price target on Acumen to $4 from $11 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
BofA
Buy
maintain
$10 -> $9
2025-08-25
Reason
BofA
Price Target
$10 -> $9
2025-08-25
maintain
Buy
Reason
BofA lowered the firm's price target on Acumen to $9 from $10 and keeps a Buy rating on the shares, citing the updated cash position following a Q2 report the firm calls "(understandably) quiet." The "key update" was the phase 2 ALTITUDE-AD of sabirnetug in early AD remains on track to read-out late 2026, the analyst added.
Citi
Buy
initiated
$4
2025-06-18
Reason
Citi
Price Target
$4
2025-06-18
initiated
Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$15 → $11
2025-03-28
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$15 → $11
2025-03-28
Maintains
Strong Buy
Reason
UBS
Colin Bristow
Strong Buy
Maintains
$6 → $4
2025-03-28
Reason
UBS
Colin Bristow
Price Target
$6 → $4
2025-03-28
Maintains
Strong Buy
Reason
UBS lowered the firm's price target on Acumen to $4 from $6 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company's cash position and the market volatility for the target cut.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Acumen Pharmaceuticals Inc (ABOS.O) is -1.29, compared to its 5-year average forward P/E of -7.22. For a more detailed relative valuation and DCF analysis to assess Acumen Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.22
Current PE
-1.29
Overvalued PE
6.63
Undervalued PE
-21.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.29
Undervalued EV/EBITDA
-9.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
114.35
Current PS
0.00
Overvalued PS
581.08
Undervalued PS
-352.38
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ABOS News & Events

Events Timeline

(ET)
2025-12-02
08:11:00
Acumen Pharmaceuticals Enhances Antibody Delivery for Alzheimer's at CTAD 2025
select
2025-11-17 (ET)
2025-11-17
08:18:16
Acumen Administers First Dose to Participant in OLE Segment of Phase 2 ALTITUDE-AD Study
select
2025-11-12 (ET)
2025-11-12
07:05:24
Acumen anticipates funding will last until early 2027.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-12Newsfilter
Acumen Pharmaceuticals Announces Financial Results and Business Highlights for Q3 2025

  • Financial Overview: Acumen Pharmaceuticals reported a cash balance of $136.1 million as of September 30, 2025, which is expected to support its clinical and operational activities into early 2027. The company experienced a decrease in both research and development expenses and net loss compared to the previous year.

  • Clinical Trials Update: The company anticipates non-clinical data for its Enhanced Brain Delivery (EBD™) program in early 2026 and expects topline results from the Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) for early Alzheimer's disease in late 2026.

  • Leadership Changes: Acumen appointed George Golumbeski, Ph.D., as the new Chairman of its Board of Directors, bringing over 30 years of biopharmaceutical experience to the company.

  • Product Development Focus: Acumen is focused on advancing sabirnetug, a monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs), which are implicated in Alzheimer's disease, and is also exploring a subcutaneous formulation using Halozyme's drug delivery technology.

[object Object]
Preview
9.0
10-23NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

  • Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

  • Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

  • Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

  • Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

[object Object]
Preview
9.0
09-29NASDAQ.COM
Biotech Surge on Friday: Clinical Advancements Drive Afternoon Gains

  • Enanta Pharmaceuticals Surge: Enanta Pharmaceuticals Inc. saw a significant after-hours increase of 20% to $9.48 following the announcement of upcoming topline results from its Phase 2b study on zelicapavir for treating RSV in high-risk adults.

  • Acumen Pharmaceuticals Rebound: Acumen Pharmaceuticals Inc. experienced a 12.67% rise in after-hours trading, driven by renewed interest in its Alzheimer's candidate, Sabirnetug, despite no new announcements on that day.

  • Delcath Systems Recovery: Delcath Systems Inc. rebounded 6.00% after hours to $11.39, likely fueled by investor interest in its CHOPIN Phase 2 trial data presentation related to a hepatic delivery system for metastatic colorectal cancer.

  • Nyxoah's Optimism: Nyxoah SA's shares rose 3.77% after hours, supported by positive investor sentiment regarding its international expansion and a recent patent infringement lawsuit against Inspire Medical Systems.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Acumen Pharmaceuticals Inc (ABOS) stock price today?

The current price of ABOS is 1.98 USD — it has increased 2.59 % in the last trading day.

arrow icon

What is Acumen Pharmaceuticals Inc (ABOS)'s business?

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

arrow icon

What is the price predicton of ABOS Stock?

Wall Street analysts forecast ABOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABOS is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Acumen Pharmaceuticals Inc (ABOS)'s revenue for the last quarter?

Acumen Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Acumen Pharmaceuticals Inc (ABOS)'s earnings per share (EPS) for the last quarter?

Acumen Pharmaceuticals Inc. EPS for the last quarter amounts to -0.44 USD, decreased -12.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Acumen Pharmaceuticals Inc (ABOS)'s fundamentals?

The market is revising No Change the revenue expectations for ABOS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 37.50%.
arrow icon

How many employees does Acumen Pharmaceuticals Inc (ABOS). have?

Acumen Pharmaceuticals Inc (ABOS) has 61 emplpoyees as of December 05 2025.

arrow icon

What is Acumen Pharmaceuticals Inc (ABOS) market cap?

Today ABOS has the market capitalization of 120.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free